Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression

Oncotarget

Volumn 7, Issue 9, 2016, Pages 10064-10072

  Wang, Qun ^a   Tan, Rong ^b   Zhu, Xin ^c   Zhang, Yi ^c   Tan, Zhiping ^c   Su, Bing ^a,b,d   Li, Yu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Central South   (China)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HDAC inhibitor; K ras; SAHA resistance

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DNA; HISTONE DEACETYLASE 6; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; RNA; VORINOSTAT; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; ENZYME INHIBITOR; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; KRAS PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; MYC PROTEIN, HUMAN; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER TISSUE; CELL GROWTH; CELL PROLIFERATION ASSAY; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIZATION; FEMALE; FIBROBLAST; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MOUSE; MUTANT; NONHUMAN; ONCOGENE K RAS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; METABOLISM; MUTATION; NEOPLASMS; NIH 3T3 CELL LINE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE; CELL LINE, TUMOR; CHROMONES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, INBRED BALB C; MICE, NUDE; MORPHOLINES; MUTATION; NEOPLASMS; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961677895     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7134     Document Type: Article

References (25)

1. Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signaling at multiple levels. Int J Biochem Cell Biol. 2009; 41:185-198.
2. Boyault C, Sadoul K, Pabion M, Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene. 2007; 26: 5468-76.
3. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. HDAC6 is a microtubuleassociated deacetylase. Nature. 2002; 417:455-8.
4. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003; 115:727-38.
5. Matthias P, Yoshida M, Khochbin S. HDAC6 a new cellular stress surveillance factor. Cell Cycle. 2008; 7:7-10.
6. Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Kamitz L, Rosen N, Neckers L. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell. 2007; 25:151-9.
7. Yang CJ, Liu YP, Dai HY, Shiue YL, Tsai CJ, Huang MS, Yeh YT. Nuclear HDAC6 inhibits invasion by suppressing NF-κB/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer. Oncotarget. 2015; 6:30263-76. doi: 10.18632/oncotarget.4749.
8. Li Y, Zhang X, Polakiewicz RD, Yao TP, Comb MJ. HDAC6 is required for EGF-induced β-catenin nuclear localization. J Biol Chem. 2008; 283:12686-90.
9. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM, Yao TP. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 2008; 68:7561-9.
10. Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012; 4:505-24.
11. Yu J, Qiu S, Ge Q, Wang Y, Wei H, Guo D, Chen S, Liu S, Li S, Xing H, Rao Q, Wang J, Wang M. A novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells. Oncotarget. 2015; 6:20121-31. doi: 10.18632/oncotarget.4041.
12. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13:673-91
13. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther. 2002; 1:937-41.
14. Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and therapeutic implications. Clin Cancer Res. 2007; 13:7237-42.
15. Bandyopadhyay D, Mishra A, Medrano EE. Overexpression of Histone deacetylase 1 confers resistance to Sodium Butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res. 2004; 64:7706-10.
16. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, Caballero R, Alaminos M, Setien F, Paz MF, Herranz M, Palacios J, Arango D. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet. 2006; 38:566-9.
17. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA, Johnstone RW. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003; 63:4460-71.
18. Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, Jones DR. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway. J Biol Chem. 2003; 278:18980-9.
19. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011; 2:344-358. doi: 10.1177/1947601911411084.
20. Prior IA, Lewis PD, Mattos C. A comprehensive survey of ras mutations in cancer. Cancer Res. 2012; 72:2457-66.
21. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66: 3992-5.
22. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013; 503:548-551.
23. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, Craddock C, Turner BM. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005; 19:1751-9.
24. Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, Kurosumi M, Saji S, Suemasu K, Okazaki T, Nakachi K, Fujita T, Hayashi S. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci. 2004; 95:496-502.
25. Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M, Toi M. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene. 2005; 24:4531-9.